Previous Close | 225.8614 |
Open | 225.8253 |
Bid | 227.4341 |
Day's Range | 225.5260 - 227.8099 |
52 Week Range | 120.4256 - 227.8099 |
Ask | 227.4366 |
DURHAM, N.C., May 09, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.